What You Need to Know About the Protein-Based Covid Vaccine Now Available for Individuals Ages 12 and Up

 

As COVID-19 continues to evolve, it is essential to consider vaccine options that provide a broad immune response against a range of variants.

 

Officials say having a diverse vaccine portfolio may help increase vaccination rates by giving people a choice in their immunization options and adding a technology platform that many are more familiar with.  As of October 2022, the Novavax COVID-19 vaccine is the first and only protein-based COVID-19 vaccine approved for use in the U.S. 

 

The Novavax COVID-19 Vaccine uses protein-based technology similar to technologies used in vaccines to protect against Hepatitis B, Flu and Whooping Cough. Now available in all 50 states, the two-dose primary series has received Emergency Use Authorization (EUA) for ages 12+ and is also currently under review by the FDA for use as a booster.

 

Last month, data presented at the World Vaccine Congress demonstrated an early indication that Novavax’s prototype vaccine may be effective against variants such as Omicron.

 

 

Safety data from the Novavax COVID-19 Vaccine’s clinical trials, both in adolescents and adults, showed the vaccine to be well-tolerated. In addition, severe adverse reactions were low in number, balanced between vaccine and placebo groups, and not considered to be related to the Novavax COVID-19 vaccine.

 

 

Novavax Executive Vice President & Chief Communications Officer Silvia Taylor joined me to share more information.

Visit vaccines.gov to learn more.

 

 

 

ABOOUT OUR GUEST

 

 

Silvia Taylor is the Executive Vice President & Chief Communications Officer for Novavax. She brings more than 25 years of communications and commercial leadership to Novavax.

 

Most recently, she was vice president of global corporate affairs and communications at Autolus Therapeutics plc, where she led all financial, scientific, and corporate communications. Prior to Autolus, Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo.

 

Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as roles at Pfizer, where she served in key brand and consumer marketing roles. She has also worked in public relations and communications roles in agency and nonprofit settings.

 

 Ms. Taylor earned a Master of Business Administration degree from Columbia University and a Bachelor of Arts degree in foreign affairs from the University of Virginia.